HTA’d in the USA: A Comparison of ICER in the United States with NICE in England and Wales.

The Institute for Clinical and Economic Review (ICER) is an independent non-profit organization in the United States that aims to evaluate the evidence of new and emerging technologies in health. Similar to the National Institute for Health and Care Excellence (NICE) in the UK and the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia, ICER is the first organization in the U.S. to address drug prices using cost-effectiveness methods.

Unlike the U.K., the U.S. does not possess a single payer system but relies on a multitude of different payers, all of which have different measures to assessing the value of a new health technology. ICER was founded in 2006 with the aim of providing a non binding evaluation of new health technologies (including drugs) in the U.S., in hopes of aligning it with the aim of an agency such as NICE in the UK.

This latest article via AMCP provides a comprehensive comparison of ICER and NICE, focusing on the structure of health technology assessment (HTA) programs, methods of HTA, processes for conduct of HTA, and use of HTAs in decision making.